Try our Advanced Search for more refined results
Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
December 16, 2025
Dana-Farber To Pay $15M To Resolve Fraud Allegations
Dana-Farber Cancer Institute will pay $15 million to settle allegations that its researchers used inaccurate images in grant applications and research articles, the U.S. Department of Justice announced Tuesday.
-
December 16, 2025
Ex-NIAID Director Claims Retaliation in Trump Admin Suit
The former director of the National Institute of Allergy and Infectious Diseases filed suit in Maryland federal court on Tuesday alleging Trump administration appointees violated her constitutional rights by illegally terminating her employment and that she cannot expect her claims to be fairly heard by the "undermined" U.S. Office of Special Counsel.
-
December 16, 2025
Samsung Wants ITC To Consider Oura Smart Ring IP Fight
Samsung has expanded its legal battle with Oura over patents covering biometric-tracking wearable technologies, telling the U.S. International Trade Commission that Oura's smart rings infringe a set of four patents owned by Samsung.
-
December 16, 2025
PE-Backed Medline Prices Long-Awaited $6.3B IPO
Private equity-backed medical supplies giant Medline, guided by Simpson Thacher & Bartlett LLP, on Tuesday priced an upsized initial public offering, raising $6.26 billion in what will be the largest IPO of 2025 just weeks before year-end.
-
December 16, 2025
Ultrahuman Loses Bids To Halt ITC Order In Oura Patent Case
The U.S. International Trade Commission and the Federal Circuit have both denied requests by Ultrahuman to stay ITC orders barring imports of its smart rings found to infringe an Ouraring patent, turning aside Ultrahuman's arguments that the orders are too broad.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals